论文部分内容阅读
目的观察干扰素α-2b联合拉米夫定治疗慢性乙型肝炎的抗病毒效果。方法80例HBsAg、HBeAg、抗HBc阳性、HBV-DNA阳性的患者,随机分为联合组和拉米夫定组,联合组同时给予拉米夫定口服100 mg/d和干扰素α-2 b 5 MU/qod肌肉注射,拉米夫定组为口服拉米夫定100 mg/d,疗程均为12个月。结果治疗结束时两组患者丙氨酸氨基转移酶、天门冬氨酸氨基转移酶复常,HBV-DNA转阴率类似,但是HBeAg阴转和HBeAg抗/HBe血清转换率,联合组明显高于拉米夫定组。结论干扰素α-2b联合拉米夫定治疗慢性乙型肝炎疗效优于单用拉米夫定。
Objective To observe the antiviral effect of interferon α-2b combined with lamivudine in the treatment of chronic hepatitis B virus. Methods Eighty patients with HBsAg, HBeAg, anti-HBc positive and HBV-DNA positive were randomly divided into combined group and lamivudine group. The combination group was given lamivudine orally 100 mg / d and interferon α-2b 5 MU / qod intramuscular injection, lamivudine group oral lamivudine 100 mg / d, treatment were 12 months. Results At the end of treatment, alanine aminotransferase and aspartate aminotransferase were normal and the rate of HBV-DNA negative conversion was similar in both groups, but the seroconversion rates of HBeAg negative and HBeAg anti-HBe in the two groups were significantly higher than those in the combined group Lamivudine group. Conclusion Interferon α-2b combined with lamivudine treatment of chronic hepatitis B is better than lamivudine alone.